Retatrutide vs Semaglutide
Ozempic, Wegovy, Rybelsus
Retatrutide (metabolic) and Semaglutide (weight loss) are evaluated side by side on Vial: Retatrutide is not FDA approved for human use with clinical-trial evidence, and Semaglutide is an FDA-approved drug with compounding now restricted with FDA-approval-level clinical evidence.
Vial summary · compiled from public records
At a glance
Semaglutide
Sold as Ozempic, Wegovy, Rybelsus
- Category
- Weight Loss
- FDA / legal status
- Compounding Restricted
- Route
- Subcutaneous, oral
Side by side
| Field | Retatrutide | Semaglutide |
|---|---|---|
| Category | Metabolic | Weight Loss |
| Brand names | — | Ozempic, Wegovy, Rybelsus |
| FDA / legal status | Gray Market | Compounding Restricted |
| Evidence tier | Clinical Trials | FDA Approved |
| Administration route | Subcutaneous | Subcutaneous, oral |
| Compounding access | Not FDA approved, limited regulated access | Compounding limited to documented case-by-case 503A need |
| Providers on Vial | 0 listed | 28 listed |
| Typical price band | Varies by provider | $ to $$ |
Verified providers offering each
Ranked by Confidence Rating, Vial’s 0 to 100 score built from federal and state public records. The score evaluates the provider, not the compound.
Retatrutide0 top providers
No surfaceable providers currently list Retatrutide on Vial.
See all 0 providers offering retatrutide →About each compound
About Retatrutide
Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously, representing the most mechanistically advanced anti-obesity peptide in late-stage clinical development. Phase II trials reported mean body weight reductions of 24% over 48 weeks — the largest pharmacological weight loss ever recorded in a randomized controlled trial. It is being developed by Eli Lilly and is expected to enter Phase III trials in 2025–2026.
About Semaglutide
A synthetic glucagon-like peptide-1 (GLP-1) receptor agonist, semaglutide mimics the incretin hormone GLP-1 to stimulate glucose-dependent insulin secretion, suppress glucagon release, and slow gastric emptying. The compound also acts on hypothalamic receptors to reduce appetite and food intake. Primary clinical applications include the management of type 2 diabetes mellitus and chronic weight management in individuals with obesity or overweight with weight-related comorbidities.
Descriptions compiled from public FDA records and manufacturer labeling where available. Not medical advice.
This page evaluates compliance signals, not clinical outcomes. Consult a licensed physician before starting any therapy, medication, or treatment. Vial does not provide medical advice.
Related compound comparisons
Other comparisons in the same category.